The company is using a recently closed funding round to drive commercialization of the test, which measures three proteins in urine to detect pancreatic cancer.

As the shutdown drags out, there could be delays in regulatory processes and payments for medical services as well as the ...

Siemens Healthineers will leverage its regional network and healthcare technology expertise to support the adoption of Aiforia's pathology tools.

Researchers hope to soon commercialize a simple, inexpensive, and accessible screening test that uses taste as a detection ...

The firm hopes to exploit its first-mover advantage in the OTC space following de novo clearance for an at-home PCR test to detect sexually transmitted infections.

Regulatory burdens have raised the capital requirements for early-stage companies, causing many to do what would have been ...

The company plans to conduct a three-year study of Parkinson's risk among people with essential tremor, using its Syn-One Test.

The new swab technology allows for non-invasive collection of patient samples without the need for liquids or complex devices.

Last week, readers were most interested in a story about alternatives to blood as sample types for diagnostic testing.

The company noted that if PAMA cuts go into effect at the beginning of next year as scheduled, they would negatively impact its 2026 revenues by around $100 million.

Saliva, sweat, and interstitial fluid have shown promise as alternative sample types in situations where blood may be too hard to access.